Spero Therapeutics Inc's Customers Performance

Name: Spero Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

SPRO

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


SPRO's Source of Revenues		• List of SPRO Customers

for the same period Spero Therapeutics Inc

• List of SPRO Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Spero Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Spero Therapeutics Inc Contracts

Navigating New Frontiers Spero Therapeutics’ Tebipenem HBr and SPR720 TrialsInnovation Amidst Challenges

Exploring Spero Therapeutics Recent Advancements and ChallengesSpero Therapeutics has been making waves in the pharmaceutical sector with its innovative drug candidates aimed at addressing serious bacterial infections and pulmonary diseases. Recent announcements regarding the company s lead antibiotic candidate, tebipenem HBr, and the investigational compound SPR720 have sparked considerable interest, particularly within the medical community. This article examines the implications of their recent clinical trial results and publications, highlighting the advancements and setbacks that paint a complex picture of Spero Therapeutics’ potential. Tebipenem HBr: A Beacon in Complicated Urinary Tract Infection...

Clearing a Path for Hope: Spero Therapeutics Advances Novel Polymyxin Antibiotic to Combat Multi-Drug Resistant Gram-Negative Bacterial Infections

In a significant development, Spero Therapeutics, a renowned clinical-stage biopharmaceutical company, has announced that its investigational new drug (IND) application for SPR206 has received clearance from the U.S. Food and Drug Administration (FDA). This achievement has opened the doors for a Phase 2 clinical study to evaluate the efficacy of SPR206, a next-generation polymyxin antibiotic, in treating hospital-acquired and ventilator-associated bacterial pneumonia caused by multi-drug resistant (MDR) Gram-negative bacterial infections.Facts:1. Spero Therapeutics, a proactive company dedicated to addressing high unmet needs in rare diseases and MDR bacterial infections, has obtained FDA clearance for its I...

SPRO's Stock Performance relative to it's Customers

SPRO's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Spero Therapeutics Inc	64.92	61.19	15.24	25
SUBTOTAL	0.00	0.00	0.00	-

Sources: Spero Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Spero Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Spero Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.